Background and Purpose: Schizophrenia is a chronic, debilitating psychiatric disorder affecting many young adult populations worldwide. Evidence from studies of central changes in the oxidative defense system suggests the involvement of oxidative stress in the pathophysiology of schizophrenia. Jobelyn® (JB) is a commercial polyherbal formulation that has been documented to show beneficial...
BACKGROUND: Longer-term outcome and safety data of repeated subcutaneous racemic ketamine for treatment-resistant depression (TRD) is lacking, as is knowledge of the impact of prior ketamine treatment on subsequent response. AIMS: To evaluate the effectiveness and safety of a 4-week course of subcutaneous racemic ketamine over 6 months and investigate whether prior ketamine treatment influences...
BACKGROUND: Neurotic disorders - major depressive disorder (MDD), panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and specific phobia - have differing pharmaceutical profiles. But all, even when resistant to conventional treatment (TR), respond quickly to low dose (0.5-1.0 mg/kg I.M.) ketamine....
Open Minds International JournalJuly 6, 2026Juliana Leite Haubman, João Octávio Celante da Silva, Bruno Horta Leonardo Machado de Moura et al.
Intravenous esketamine represents a significant therapeutic innovation in the field of psychiatry, particularly in the management of treatment-resistant depression and severe psychiatric conditions associated with suicidal ideation.Derived from the S-enantiomer of ketamine, esketamine acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, promoting rapid glutamatergic modulation...
Treatment-resistant depression (TRD) remains a major clinical challenge, with highly variable responses to ketamine. Immune activation characterizes a subset of patients with TRD. The kynurenine pathway (KP), which integrates immunometabolic signals with glutamatergic neurotransmission, may provide candidate biomarkers to inform personalized treatment. We investigated whether KP metabolites and...
Ketamine is a fast-acting intervention for treatment-resistant depression (TRD), yet only a subset of patients show robust clinical response, and the underlying neural mechanisms remain unclear. High-order interactions (HOI) derived from multivariate information theory provide a framework for examining nonlinear dependencies among brain regions beyond pairwise connectivity. One such metric, the...
Background: Ketamine, a dissociative anesthetic, is widely used in experimental schizophrenia models due to its ability to mimic psychotic symptoms through N-methyl-D-aspartate (NMDA) receptor antagonism. Despite its utility, concerns remain regarding its potential systemic toxicity, particularly in the liver and kidneys. Method: This study investigated the dose- and time-dependent hepatotoxic...
Depression involves dysregulation across distributed cortico-limbic circuits, and ketamine is notable for its rapid antidepressant effects. Although depression and ketamine treatment have been linked to altered brain network topology, how within-frequency and cross-frequency coupling are jointly reorganized at the brain-wide level remains unclear. Here, we developed a frequency-varying...
Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of benefit, durability, and key harms. This systematic review and meta-analysis included randomized controlled trials comparing intranasal...
Journal of Psychoactive DrugsJuly 3, 2026Miguel Joaquim Soares Teles Couceiro, Victor José da Conceição Teixeira Amorim Rodrigues, Nuno Manuel Correia Torres
This case study explores the potential role of mystical-type experiences in ketamine-assisted psychotherapy (KAP). A patient with generalized anxiety disorder and migraines underwent four intramuscular KAP sessions (0.5-0.9 mg/kg). Outcomes were assessed using the Outcome Questionnaire-45 (OQ-45), the Hood Mysticism Scale (HMS), and interviews. Greater therapeutic gains followed sessions with...